Finally, the synergy between RGR-TRAIL and EGFR-targeted PDT was evaluated in mice bearing tumor grafts of CRC cells with both chemotherapeutic MDR and TRAIL resistance. This evidence concerns the gene EGFR and colorectal carcinoma.